ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

5 Healthcare Picks for Your Income Portfolio: GSK, SNY, LLY, BMY, NVS

Share On Facebook
share on Linkedin
Print

GlaxoSmithKline plc (NYSE:GSK): The stock offers healthy dividend yield of 5.01 percent. It also provided 8.24 percent capital appreciation in 2013 so far. GlaxoSmithKline develops and markets pharma products and therapies.

The company is operational globally and also deals in health related consumer products. The company stock is currently trading at $47.20, up 0.28 percent from its previous close of $47.0. The stock had opened at $47.25 and has traded in the range of $47.01 and $47.25 in the current trading session. It has traded 1.292 million shares as of now. GlaxoSmithKline stock is currently trading above its 20 days moving average price of $47.18, indicating bullish trend. GlaxoSmithKline commands market capitalization of $115.82 billion and its Price Earnings ratio is 17.07. The company recently announced the launch of the third phase of Benlysta trial. The drug is being tested for the treatment of ANCA-positive vasculitis.

Sanofi (NYSE:SNY): The stock is trading 0.37 percent higher, at $51.19. The company has traded 1.06 million shares in the current trading sessions so far and its stock has traded in the range of $33.03 and $52.09 in the past 52 weeks, offering 38.22 percent return. Sanofi is an ideal candidate for an income portfolio as it provides healthy 3.68 percent dividend yield along with robust capital gain. The company develops and markets vaccines and pharmaceuticals. It distributes its products through wholesalers, distributors and physicians. The company stock’s beta is 0.89, while its P/E ratio stands at 20.99. It had reported its latest Earnings per Share at $2.44. Sanofi was earlier known as Bristol-Aventis and it changed its name in 2011. The company is based out of Paris and was established in 1970. Sanofi has collaboration with major pharma companies like Warner Chilcott.

Eli Lilly and Company (NYSE:LLY): The stock is rated Outperform by Sanford C. Bernstein and its price target is set at $61. The stock is trading at $56.87, 0.09 percent higher than its previous close. It has traded in the range of $56.80 and $57.23 in the current trading session. It has traded 538,667 shares so far, in comparison to its daily average trading volume of 4.51 million shares. The stock has traded in the range of $39.16 and $57.28 in the past 52 weeks and grew 43.25 percent during the same time period. The company stock trades at Price Earnings ratio of 15.55 and its beta is at 0.69. Eli Lilly also supplements its return by offering 3.47 percent dividend yield. The company develops and markets pharma products and specializes in therapies for bipolar disorder and schizophrenia. It is scheduled to announce its first quarter results on April 24th, 2013. Eli Lilly is based out of Indiana.

Bristol Myers Squibb Company (NYSE:BMY): it offers 3.40 percent dividend yield and the stock appreciated 23.4 percent in the past 52 weeks, offering solid return to its investors. Its stock traded in the range of $40.67 and $41.00 in the current trading session and at this point is at $40.76, up 0.07 percent. The stock’s highest price point of 52 weeks stands at $41.79 while its lowest price point is at $40.67. Bristol Myers Squibb stock is trading at Price Earnings ratio of 35.36 and its beta is 0.45. It is trading above its 20 days and 50 days moving average price of $39.94 and $38.05 respectively, indicating bullish trend. Bristol Myers Squibb recently announced that it will be closing its Amylin Pharmaceuticals’ headquarters. It will also curtail about 300 positions there. The headquarter will be completely closed by March, 2015. Bristol Myers Squibb had bought Amylin in August last year. The acquisition is expected to help the company is consolidating its position in diabetes market.

Novartis AG (NYSE:NVS): The company deals in patented prescription medicines and focuses on developing therapies for cardiovascular and respiratory ailments. Its stock served the investors well by offering 2.20 percent dividend yield and it also appreciated 30.63 percent in the past 52 weeks. It is currently trading at $71.47, down 0.14 percent. It is trading in the range of $71.17 and $71.74 in the current trading session. The stock is higher than its 20 days moving average price of $70.41 and 50 days moving average price of $69.20. In the past 52 weeks, the stock’s price range has been $51.20 and $71.99. The stock’s beta is 0.56 and its Price Earnings ratio is 18.38. Novartis commands market capitalization of $173 billion.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com